drugset / Trial / NCT07235176
Phase Ib/II Clinical Study of QLS1304 Combined With Endocrine Therapy in the Treatment of ER+/HER2- Breast Cancer Patients
Non-randomizedSingle-groupOpen-labelTreatment
Summary
This study is a multi-center, open label, phase Ib/II clinical trial aimed at evaluating the safety, preliminary efficacy characteristic and PK characteristics of QLS1304 in combined with endocrine therapy in ER+/HER2- breast cancer patients. This study was divided into two stages: combo dose escalation and dose expansion.
Timeline
- Start
- 2026-01-16
- Primary completion
- 2028-11-02
- Completion
- 2031-12-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Fulvestrant | Small molecule | — | — |
| Subject | QLC1401 | Unknown | — | — |
| Subject | QLS1304 | Unknown | — | — |